Outfitter Advisors LTD. acquired a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,829 shares of the biotechnology company’s stock, valued at approximately $3,357,000. Outfitter Advisors LTD. owned about 0.05% of Bioverativ as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently bought and sold shares of the company. Whittier Trust Co. of Nevada Inc. purchased a new stake in Bioverativ during the third quarter valued at $293,000. Quotient Investors LLC purchased a new stake in Bioverativ in the third quarter worth about $420,000. Rockefeller Financial Services Inc. purchased a new stake in Bioverativ in the third quarter worth about $1,480,000. Tirschwell & Loewy Inc. purchased a new stake in Bioverativ in the third quarter worth about $2,068,000. Finally, Meeder Asset Management Inc. purchased a new stake in Bioverativ in the third quarter worth about $877,000. Institutional investors own 93.07% of the company’s stock.
Bioverativ Inc (NASDAQ:BIVV) traded down $0.46 during trading hours on Monday, hitting $53.55. The company had a trading volume of 279,302 shares, compared to its average volume of 1,123,070. Bioverativ Inc has a 12-month low of $40.00 and a 12-month high of $64.41.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm’s revenue was up 27.2% compared to the same quarter last year. analysts forecast that Bioverativ Inc will post 2.45 EPS for the current fiscal year.
WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/11/06/outfitter-advisors-ltd-acquires-new-stake-in-bioverativ-inc-bivv.html.
A number of analysts have commented on the company. Zacks Investment Research upgraded Bioverativ from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Morgan Stanley restated an “underweight” rating and issued a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Cowen and Company upgraded Bioverativ from a “market perform” rating to an “outperform” rating in a research report on Monday, July 10th. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a research report on Monday, October 23rd. Finally, Royal Bank Of Canada assumed coverage on Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price target for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Bioverativ has a consensus rating of “Hold” and an average target price of $61.73.
In other news, Director Brian S. Posner acquired 1,000 shares of Bioverativ stock in a transaction on Wednesday, August 9th. The shares were bought at an average cost of $59.19 per share, for a total transaction of $59,190.00. Following the acquisition, the director now directly owns 6,693 shares of the company’s stock, valued at approximately $396,158.67. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
What are top analysts saying about Bioverativ Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ Inc and related companies.